New Generation Cell Therapy:
Bioartificial Pancreas to Cure Type 1 Diabetes

Why needed?

Forty million individuals worldwide suffer from type 1 diabetes. This disease is managed by insulin therapy in a vast majority of patients because of the limited accessibility of beta cell replacement therapies.

There is an urgent need for the development of a beta cell replacement therapy that will be available to larger numbers of type 1 diabetic patients.

Our solution​

The VANGUARD project aims to generate a vascularized and immune-protected bioartificial pancreas that can be transplanted into non-immuno-suppressed patients by combining advanced tissue engineering strategies.

This approach will yield a cell therapy in the form of an Advanced Therapy Medicinal Product (ATMP), which can significantly improve treatment of type 1 diabetes.

Project overview

  • Consortium

    9 partners from 5 countries

  • Budget

    € 6.8 million

  • Duration

    01.01.2020 – 31.12.2024


Watch the VANGUARD project video online

During the annual VANGUARD project meeting 2022 held in Geneva, Switzerland we spoke to all project partners involved about the objectives of VANGUARD, their role